Cooperative Agreement U01CA282212
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$640K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Cooperative Agreement
Place of Performance
Stanford, CA 94305, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $148,568 Project Grant to The Leland Stanford Junior University (Stanford University) under the NCI's Cancer Research Manpower (CFDA 93.398) program. The grant, which runs from December 17, 2024 to July 14, 2027, supports research to integrate highly multiplexed immunofluorescence with label-free 2D hyperspectral chemical imaging to interrogate the colorectal cancer tumor-invasive front. This innovative approach aims to enhance the understanding of...
This $692,491 Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research to develop a minimally-invasive blood test for multi-cancer detection and determination of tissue of origin preceding overt cancer diagnosis. The primary goal is to investigate early epigenetic signatures for common cancers, including prostate, lung, colorectal, and ovarian cancer, using the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Leland Stanford Junior University (Stanford University) for $170,376. The grant, awarded on April 9, 2025, supports the development of a rapid, label-free, and cost-effective technique to quantify chimeric antigen receptor (CAR) T cells in patient blood samples using surface-enhanced Raman spectroscopy (SERS) and machine learning. This research aims to...
This $2,136,715 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) is focused on harnessing DNA methylation in peripheral blood to improve colorectal cancer prevention. The primary awardee, President and Fellows of Harvard College through its Harvard T.H. Chan School of Public Health, will lead the research effort. Key sub-awards have been made to Dana-Farber Cancer Institute and Boston University to contribute...
The National Cancer Institute (NCI) awarded a Project Grant under the CFDA 93.394 Cancer Detection and Diagnosis Research program to Exai Bio Inc., a small disadvantaged business located in Palo Alto, California. The $1,280,908 grant, awarded on September 12, 2024, supports the development of a novel liquid biopsy assay and artificial intelligence (AI) model for early detection of non-small cell lung cancer (NSCLC) and prediction of cancer subtypes. The project aims to gather samples and test...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $670,534 to Northwestern University to develop an optical hyperspectral nanoscale chromatin analysis technology for colorectal cancer risk-stratification. The goal is to create a highly accurate, low-cost screening test that can be administered in primary care settings to identify patients who should undergo colonoscopy, with a target of 99.5% negative predictive...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Leland Stanford Junior University (Stanford University) provides $648,428.00 in funding over a 5-year period from December 2024 to November 2029. The award supports innovative research aimed at identifying key tumor microenvironmental features that contribute to the transition from pre-invasive ductal carcinoma in situ (DCIS) to invasive breast cancer. The project...
The National Cancer Institute (NCI) awarded a $135,594 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Leland Stanford Junior University (Stanford University) to develop novel pharmacological approaches to rewire oncogenic gene expression and induce cancer cell death. The key objectives are to: 1) Develop small molecule chemical inducers of proximity (CIPs) that can target and kill aggressive leukemias driven by mixed-lineage leukemia (MLL) fusion oncogenes, and...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award of $560,297 to the Icahn School of Medicine at Mount Sinai supports research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The key objectives are to: Generate phenotypic transcriptional reporters to track the dynamics of LGR5+ cancer stem cells (CSCs) and ONFSCs, and use these to dissect the functional interplay between these stem cell populations. Employ a multi-omic...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $872,555 to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA over a five-year period from September 1, 2024 to August 31, 2029. The award aims to catalyze long-read cancer genome sequencing efforts through the development of informatic methods for the discovery and characterization of somatic genetic alterations in cancer genomes. Key objectives include improving...